Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Kitware, a leader in data visualization, ... the exploration of hospital costs across the United ... the recent release of “Medicare Provider Charge Data,” a ... procedures from the Centers for Medicare & Medicaid Services. ... at hospitals across the country has sparked considerable controversy; ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 The JM ... media training online, has proudly announced that the company's ... business has surpassed 175,000 views on YouTube. The company ... media and SEO tips and training for small businesses ... students find the YouTube tips helpful for their SEO ...
(Date:5/17/2013)... recipient,s immune system identifies the transplanted organ as foreign ... T cells, the immune cells that mediate rejection, must ... order to migrate to the transplanted organ. In this ... Fadi Lakkis and colleagues at the University of Pittsburgh ... cells is not required for migration. Instead, these cells ...
(Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3
... Eindhoven University of Technology (TU/e) has appointed prof. dr. Stuart ... professor at Stanford University and an IBM Fellow of the ... he was awarded an honorary doctorate by TU/e. Parkin is ... is the first ,distinguished professor, of TU/e, an international top ...
... ANGELES, Oct. 20 Humanitarian, Dr. Gary Michelson,is ... animals,",says Aimee Gilbreath, Executive Director of Found Animals ... 501(c)3., Found Animals and its strategic partner ... announced the launch of The Michelson Prize in,Reproductive ...
... directors,of Eli Lilly and Company (NYSE: LLY ) today ... a share on outstanding common stock. This,is the same dividend ... and,brings the total annual dividend for 2008 to $1.88 per ... shareholders of record at,the close of business on November 14, ...
Cached Biology Technology:Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
(Date:5/16/2013)... million years old give unprecedented insight into the ... the most species-rich groups among the modern bony ... Reichenbacher from the Division of Paleontology and Geobiology ... at Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have ... they assign to the group of bony fishes ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... rabbis from the Orthodox Union started finding worms in ... scientists at the American Museum of Natural History to ... still be considered kosher? Using a technique called ... Genomics, researchers identified the species and life cycles of ...
... bacteria first found in Yellowstone,s hot springs are furthering ... toward commercially viable ethanol production from crops such as ... relies on the use of expensive enzymes that break ... fermented into ethanol. One suggested cheaper alternative is consolidated ...
... Institute have identified a subtype of ovarian cancer able to ... be especially susceptible to "anti-angiogenic" drugs that block blood vessel ... PloS ONE , the investigators estimate that the subtype ... a common cancer of the surface of the ovaries. ...
Cached Biology News:DNA barcoding of parasitic worms: Is it kosher? 2ORNL explores proteins in Yellowstone bacteria for biofuel inspiration 2New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs 2New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs 3
Request Info...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
...
Biology Products: